The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

North America held the largest rituximab biosimilars market share, and Middle East was the fastest-growing region in 2022.

The global rituximab biosimilars market is expected to grow from $2.05 billion in 2022 to $2.35 billion in 2023 at a compound annual growth rate (CAGR) of 14.5%. The rituximab biosimilars market is expected to grow from $3.84 billion in 2027 at a CAGR of 13.1%.

Major Driver In The Rituximab Biosimilars Market ­– Rise In The Prevalence Of Non-Hodgkin’s Lymphoma
NHL is the most frequent disease in the United States, accounting for around 4% of all cancers, according to the American disease Society. In 2021, approximately 81,560 persons (45,630 men and 35,930 women) in the United States will be diagnosed with NHL.Thus, rising non-Hodgkin’s lymphoma cases are expected to drive up demand for rituximab biosimilars over the projection period.

View More On The Rituximab Biosimilars Market Report 2023 – https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report

Key Rituximab Biosimilars Market Segments
1) By Application: Non-Hodgkin’s Lymphoma, Chronic Lymhocytic Leukemia, Rheumatoid Arthritis, Other Applications
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Direct Distribution Channels
3) By Route Of Administration: Subcutaneous, Intravenous, Molecular Type

Recent Rituximab Biosimilars Market Trend – New Product Development In Collaboration
Companies in the biosimilars sector are always working on new product development in conjunction with other companies in the industry. Partnership-driven innovation is altering the market for rituximab biosimilars. Teva Pharmaceutical Industries Ltd. and Celltrion Healthcare Co. Ltd., for example, announced the launch of biosimilar Truxima (rituximab-abbs) injection in the United States in May 2020 for the treatment of polyangiitis and rheumatoid arthritis. Truxima is the only biosimilar to Roche’s Rituxan (rituximab) that is approved for the treatment of rheumatoid arthritis in the United States.

Rituximab Biosimilars Market Prominent Players
Major players in the rituximab biosimilars market are Pfizer Inc., Mylan Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., and Celltrion Healthcare Co. Ltd., Sandoz International GmbH, Reliance Life Sciences, C.H. Boehringer Sohn AG & Co. KG, BioXpress Therapeutics SA, and Intas Biopharmaceuticals Ltd.

Request A Sample Of The Global Rituximab Biosimilars Market Report 2023:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3430&type=smp

The Rituximab Biosimilars Global Market Report 2023  provides a comprehensive overview on the rituximab biosimilars market size, trends and drivers, opportunities, strategies, and companies analysis. The countries covered in the rituximab biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Rituximab biosimilar is a chimeric monoclonal antibody aimed against the B cell-specific protein CD20 in the immune system. Rituximab destroys B cells, making it useful for treating illnesses characterised by an excess of B cells, excessive activity, or other abnormalities.

View More Related Reports –
Biosimilars Global Market Report 2023
Biosimilar Monoclonal Antibodies Global Market Report 2023
Cancer Monoclonal Antibodies Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model